4.7 Article

A bispecific immunotoxin (IHPP) with a long half-life targeting HER2 and PDGFRβ exhibited improved efficacy against HER2-positive tumors in a mouse xenograft model

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 592, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ijpharm.2020.120037

Keywords

Bispecific immunotoxin; PE toxin; HER2-target; PDGER beta-target; Transcriptome sequencing

Funding

  1. National Natural Science Foundation of China [81803076, 81800792, 81900392, 81771226, U1804186]
  2. Key Science and Technology Program of Henan Province [182102310436, 192102310414]
  3. Science and Technology Project for Young Talents of Henan Province [2020HYTP048]
  4. Xinxiang Scientific and Technological Project [GG2019009]
  5. Key Scientific Research Project in Henan Colleges and Universities [19A180027]
  6. Henan Province University Youth Researcher Support Program project [19IRTSTHN003]
  7. Xinxiang Foundation [20172DCG-03, ZD17008]

Ask authors/readers for more resources

Multiple signaling pathways are involved in tumor development, making bispecific antibodies more suitable for treating complex tumor diseases. A novel PE-based bispecific immunotoxin designed in this study showed improved efficacy against HER2-positive tumors. Transcriptome sequencing and real-time PCR were used to verify the results, indicating the potential of these bispecific immunotoxins for anti-HER2 cancer therapeutics.
Multiple signaling pathways are usually involved in the development of tumors. Compared with monospecific antibodies, bispecific antibodies can recognize two different antigens at the same time, so they are more suitable for treating tumor diseases with complex etiology. Immunotoxins have good antitumor activity, however, single targeting limits their effectiveness. Herein, we designed a Pseudomonas exotoxin A (PE)-based bispecific immunotoxin IgBD-HER2-PDGFR beta-PE38 which could distinguish HER2 and PDGFR beta target in tumor. Meanwhile, IgG-affinity could extend the serum retention of immunotoxins after in vivo injection. In this work, we first detected the selective binding of the immunotoxins and antitumor effect in vitro. Compared with control group, IgBD-HER2-PDGFR beta-PE38 exhibited improved efficacy against HER2-positive tumors in an NCI-N87 subcutaneous xenograft model. Then, transcriptome sequencing was performed on tumor tissue originating from different treatment groups of mice bearing NCI-N87 tumors. Seven significantly differentially expressed genes were screened based on human genes, and the differential mouse genes were enriched based on the Reactome Pathway Database. At last, the RNA sequencing results were verified by real-time PCR and ELISA. Therefore, the new construct bispecific immunotoxin represents a potentially attractive therapeutic modality, and the proposed strategy make them promising for use in the development of anti-HER2 cancer therapeutics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available